| Filed On | Filing |
|---|---|
| 26 Sep 2025 |
8-K: Termination of a Material Definitive Agreement; Material Modification to Rights of Security Holders
This LEASE TERMINATION AGREEMENT AND AMENDMENT (this “Agreement”) is entered into as of September 24, 2025 (the “Effective Date”) by and between BAYSIDE AREA DEVELOPMENT, LLC, a Delaware limited liability company (“Landlord”), and UNITY ... |
| 19 Sep 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On September 18, 2025, Unity Biotechnology, Inc. (the “Company”) held a special meeting of stockholders (the “Special Meeting”). As of the close of business on July 25, 2025, the record date for the Special Meeting (the “Record Date”), t... |
| 22 Jul 2025 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +2 more
THIS PURCHASE AGREEMENT (this “Agreement”) is made as of July 22, 2025, by and between the purchaser listed on Exhibit A attached hereto (the “Purchaser”) and Unity Biotechnology, Inc., a Delaware corporation (the “Company”). |
| 30 Jun 2025 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule; Departure/Election of Directors or Officers; Compensation +1 more
This Plan of Complete Liquidation and Dissolution (the “Plan”) is intended to constitute a plan of distribution under Section 281(b) of the General Corporation Law of the State of Delaware (“DGCL”) and accomplish the complete liquidation... |
| 20 Jun 2025 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
On June 18, 2025, Unity Biotechnology, Inc. (the “Company”) received a notification from The Nasdaq Stock Market (“Nasdaq”) that for the last 30 consecutive business days, the closing bid price of the Company’s common stock was below $1.... |
| 05 May 2025 |
8-K: Costs Associated with Exit or Disposal Activities; Departure/Election of Directors or Officers; Compensation +1 more
UNITY Biotechnology Announces Complete 36-Week Results from the ASPIRE Phase 2b Study of UBX1325 in Diabetic Macular Edema and Provides Corporate Updates |
| 22 Apr 2025 |
8-K: Results of Operations and Financial Condition
SOUTH SAN FRANCISCO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results... |
| 04 Apr 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
On April 3, 2025, Paul L. Berns informed the Board of Directors (the “Board”) of UNITY Biotechnology, Inc. (“Unity” or the “Company”) of his resignation as a member of the Board of the Company, and all of the committees of the Board on w... |
| 24 Mar 2025 |
8-K: Other Events
Treatment with UBX1325 resulted in vision gains comparable to aflibercept at weeks 24 and 36 in difficult-to-treat patient population |
| 17 Mar 2025 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
On March 14, 2025, UNITY Biotechnology, Inc. (“Unity” or the “Company”) received a letter from The Nasdaq Stock Market (“Nasdaq”) notifying the Company that its stockholders’ equity as reported in its Annual Report on Form 10-K had falle... |
| 10 Mar 2025 |
8-K: Changes in Control of Registrant; Other Events
SAN FRANCISCO, Calif., March 10, 2025 – UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that Yehia Hashad, M.D., executive vi... |
| 07 Mar 2025 |
8-K: Results of Operations and Financial Condition
SOUTH SAN FRANCISCO, Calif., March 7, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results ... |
| 06 Jan 2025 |
8-K: Other Events
SAN FRANCISCO, Calif., January 6, 2025 - UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today strengthened the executive leadership team with... |
| 04 Nov 2024 |
8-K: Results of Operations and Financial Condition
SOUTH SAN FRANCISCO, Calif., November 4, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial resul... |
| 06 Aug 2024 |
8-K: Results of Operations and Financial Condition
SOUTH SAN FRANCISCO, Calif., August 6, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results... |
| 21 Jun 2024 |
8-K: Submission of Matters to a Vote of Security Holders
On June 21, 2024, Unity Biotechnology, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders voted on four proposals, each of which is described in more det... |
| 14 May 2024 |
8-K: Results of Operations and Financial Condition
SOUTH SAN FRANCISCO, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results f... |
| 15 Apr 2024 |
8-K: Results of Operations and Financial Condition
SOUTH SAN FRANCISCO, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results... |
| 20 Mar 2024 |
8-K: Non-Reliance on Previously Issued Financial Statements
On March 19, 2024, the Audit Committee (the “Audit Committee”) of the Board of Directors of UNITY Biotechnology, Inc. (the “Company”), after consultation with management, determined that the Company incorrectly classified its warrants (t... |
| 13 Nov 2023 |
8-K: Results of Operations and Financial Condition
SOUTH SAN FRANCISCO, Calif., November 13, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial resu... |
Loading...